# Stella Xu

> Stella Xu is a Series B investor at ARMO BioSciences backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [ARMO BioSciences](https://shizune.co/investors/profile/armo-biosciences)
- Total investments: 7
- Last investment: Sep 2021
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/stellaxu/

Stella Xu is a Series B investor at ARMO BioSciences focused on Biotechnology and Health Care. Stella Xu, Ph.D. has served as a member of our board of directors since November 2018. Dr. Xu has served as Managing Director of Quan Capital, a life sciences venture fund with offices in China and the United States, since August 2017. Prior to joining Quan Capital, Dr. Xu served as Vice President and site head of Roche Innovation Center Shanghai,and a member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases Discovery and Translation Area, from September 2012 to August 2017. Dr. Xu joined Roche from McKinsey & Company. Dr. Xu has served as a director of Centrexion Therapeutics Corporation, a biopharmaceutical company focused on the treatment of chronic pain, since January 2018 and previously served as a director of ARMO BioSciences, Inc., a late-stage biopharmaceutical company focused on immuno-oncology, from August 2017 to July 2018 when it was acquired by Eli Lilly and Company. Dr. Xu received a B.S. in biophysics from Peking University and a Ph.D. in immunology from Northwestern University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 86% |
| Health Care | 4 | 57% |
| Life Science | 2 | 29% |
| Medical | 1 | 14% |
| Biopharma | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Series A | 2 | 29% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Walking Fish Therapeutics | Walking Fish Therapeutics is developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies. | $50M | Series A | Sep 13, 2021 |  |
| Design Therapeutics | Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $125M | Series B | Jan 27, 2021 |  |
| Design Therapeutics | Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. | $45.5M | Series A | Mar 20, 2020 |  |
| NextCure | NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. | $93M | Series B | Nov 13, 2018 |  |
| Tempest Therapeutics | Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California. | $70M | Series B | Mar 28, 2018 |  |
| Centrexion Therapeutics | Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm. | $67M | Series D | Jan 02, 2018 |  |
| ARMO BioSciences | ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California. | $67M | Series C | Aug 29, 2017 |  |

7 of 7 investments shown.

## Co-investors
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 2 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 2 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 2 deals together
- [WestRiver Group](https://shizune.co/investors/profile/westriver-group) — VC Fund, 2 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 1 deal together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 1 deal together

## About ARMO BioSciences

VC Fund · Redwood City, United States

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

2 contacts available at ARMO BioSciences.

| Name | Title | Profile |
| --- | --- | --- |
| Stella Xu | Board Of Directors | https://shizune.co/investors/profile/stella-xu |
| Peter Van Vlasselaer | CEO | https://shizune.co/investors/profile/peter-van-vlasselaer |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Stella Xu invest in?

Stella Xu invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Stella Xu last invest?

The most recent investment recorded for Stella Xu closed in Sep 2021. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co